About Solute carrier family 25 member 35
Solute carrier family 25 member 35 (SLC25A35) is a protein
from Homo sapiens identified by UniProt accession
Q3KQZ1, 300 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Solute carrier family 25 member 35 |
|---|
| UniProt accession | Q3KQZ1 |
|---|
| Gene | SLC25A35 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (30)
Diseases linked to this target (Open Targets).
- cardiac arrhythmia · score 0.20
- leukocyte count · score 0.17
- Immature Reticulocyte Fraction Measurement · score 0.16
- reticulocyte count · score 0.14
- BMI-adjusted waist-hip ratio · score 0.12
- serum gamma-glutamyl transferase measurement · score 0.10
- lymphocyte count · score 0.10
- low density lipoprotein cholesterol measurement · score 0.10
- hemoglobin measurement · score 0.09
- platelet component distribution width · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q3KQZ1-F1 | alphafold | PREDICTED | 87.97 | — |
Amino-acid sequence (300 residues)
MDFLMSGLAA CGACVFTNPL EVVKTRMQLQ GELQAPGTYQ RHYRNVFHAF ITIGKVDGLA ALQKGLAPAL LYQFLMNGIR LGTYGLAEAG GYLHTAEGTH SPARSAAAGA MAGVMGAYLG SPIYMVKTHL QAQAASEIAV GHQYKHQGMF QALTEIGQKH GLVGLWRGAL GGLPRVIVGS STQLCTFSST KDLLSQWEIF PPQSWKLALV AAMMSGIAVV LAMAPFDVAC TRLYNQPTDA QGKGLMYRGI LDALLQTART EGIFGMYKGI GASYFRLGPH TILSLFFWDQ LRSLYYTDTK
Explore Solute carrier family 25 member 35 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets